跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 4 小时前AI 评分40

Erasca 和 Alterome 在 KRAS 会议上的竞争态势

KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach

AI 导读

Erasca 在 KRAS 会议上展示了其胰腺癌药物的强劲数据,而 Revolution Medicines 也在同一会议上发布了积极结果。竞争正在加剧。

正文

Rev­o­lu­tion Med­i­cines post­ed strong da­ta on its tar­get­ed pan­cre­at­ic can­cer drug Thurs­day evening, but com­pe­ti­tion is build­ing at every turn in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news